Oncogenic Chromatin Remodeling and Anticancer Mechanisms
致癌染色质重塑和抗癌机制
基本信息
- 批准号:10646923
- 负责人:
- 金额:$ 45.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-08 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:ARID1A geneAntineoplastic AgentsCCI-779Cancer BiologyCancer PatientChromatinChromatin Remodeling FactorClinicalComplexDataDevelopmentDiseaseFDA approvedFRAP1 geneGenetic TranscriptionGrowthHumanKnowledgeLeadMalignant NeoplasmsMediatingMolecularOncogenicOncologyOutcomePathway interactionsPharmaceutical PreparationsPhosphorylationPhysiologyPlayProtein KinaseProteinsPublishingRegulationResistanceRoleSWI/SNF Family ComplexSerineSignal PathwaySignal TransductionSirolimusSomatic MutationTestingTherapeuticTumor Suppressor Proteinsanti-cancercancer therapycancer typechromatin remodelingepigenetic regulationimprovedin vivoinhibitorpublic health relevanceresponsetargeted cancer therapytargeted treatmenttherapy resistanttreatment responsetumortumorigenesis
项目摘要
ABSTRACT
The SWI/SNF chromatin remodeling complexes impart epigenetic regulation and control accessibility of
chromatin to transcriptional machineries. Chromatin remodeling plays important roles in normal physiology and
diseases, particularly cancer. ARID1A is a component of the BAF SWI/SNF complex and a major tumor
suppressor. ARID1A is inactivated by somatic mutations in a wide spectrum of cancer types. Despite the
apparent importance of SWI/SNF chromatin remodelers in cancer, their regulation by growth and oncogenic
signals remains not well understood. mTOR complex 1 (mTORC1) is a conserved protein kinase and a central
growth controller. mTORC1 is an oncogenic driver and the target of US FDA-approved oncology drugs
rapamycin and rapamycin analogs. Our preliminary data revealed that mTORC1 promotes proteasomal
degradation of ARID1A protein. Moreover, ARID1A plays an important role in therapeutic response and
resistance to mTORC1 inhibitors. Because mTOR pathway is estimated to be activated in nearly half of all human
tumors, mTOR-dependent degradation represents a common mechanism to inactivate the ARID1A tumor
suppressor in cancer. Therefore, it is important to understand the underlying regulatory mechanisms and its role
in cancer biology and therapy. There are two specific aims in this application: Aim 1 will dissect the molecular
mechanism by which mTORC1 regulates ARID1A and oncogenic chromatin remodeling. Aim 2 will investigate
the significance of mTORC1-dependent ARID1A regulation in tumorigenesis and anticancer drug response. Our
studies are anticipated to fill a knowledge gap in the regulation of the ARID1A tumor suppressor in tumorigenesis
and anticancer drug response/resistance. If successful, this project could lead to better strategies to target mTOR
pathway, improving clinical outcomes for cancer patients.
抽象的
SWI/SNF 染色质重塑复合物赋予表观遗传调控并控制染色质的可及性
染色质到转录机器。染色质重塑在正常生理和
疾病,特别是癌症。 ARID1A 是 BAF SWI/SNF 复合体的组成部分,也是一种主要肿瘤
抑制器。 ARID1A 在多种癌症类型中会因体细胞突变而失活。尽管
SWI/SNF 染色质重塑剂在癌症中的明显重要性及其对生长和致癌的调节
信号仍然没有得到很好的理解。 mTOR 复合物 1 (mTORC1) 是一种保守的蛋白激酶,
生长控制器。 mTORC1 是一种致癌驱动因素,也是美国 FDA 批准的肿瘤药物的靶标
雷帕霉素和雷帕霉素类似物。我们的初步数据显示 mTORC1 促进蛋白酶体
ARID1A 蛋白的降解。此外,ARID1A 在治疗反应和
对 mTORC1 抑制剂的耐药性。因为 mTOR 通路估计在近一半的人类中被激活
肿瘤中,mTOR 依赖性降解代表了 ARID1A 肿瘤失活的常见机制
癌症中的抑制剂。因此,了解潜在的监管机制及其作用非常重要
在癌症生物学和治疗方面。此应用程序有两个具体目标: 目标 1 将剖析分子
mTORC1 调节 ARID1A 和致癌染色质重塑的机制。目标 2 将进行调查
mTORC1 依赖性 ARID1A 调节在肿瘤发生和抗癌药物反应中的重要性。我们的
研究预计将填补 ARID1A 肿瘤抑制因子在肿瘤发生中调节的知识空白
和抗癌药物反应/耐药性。如果成功,该项目可能会带来更好的针对 mTOR 的策略
途径,改善癌症患者的临床结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN ZHENG其他文献
STEVEN ZHENG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN ZHENG', 18)}}的其他基金
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis
氨基酸-Rab1A 营养信号在血糖稳态调节中的作用
- 批准号:
10461838 - 财政年份:2020
- 资助金额:
$ 45.31万 - 项目类别:
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis
氨基酸-Rab1A 营养信号在血糖稳态调节中的作用
- 批准号:
10266843 - 财政年份:2020
- 资助金额:
$ 45.31万 - 项目类别:
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis
氨基酸-Rab1A 营养信号在血糖稳态调节中的作用
- 批准号:
10684889 - 财政年份:2020
- 资助金额:
$ 45.31万 - 项目类别:
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer
mTOR 激酶抑制剂在结直肠癌中的作用机制
- 批准号:
8761387 - 财政年份:2013
- 资助金额:
$ 45.31万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 45.31万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 45.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 45.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 45.31万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 45.31万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 45.31万 - 项目类别:














{{item.name}}会员




